Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS
Status:
Unknown status
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Clopidogrel, in addition to aspirin, is the cornerstone of therapy in patients suffering from
Acute coronary syndrome. However, the platelet inhibitory response to clopidogrel varies
substantially among individuals. Several loss-of-function polymorphisms have been identified
that may influence clinical outcome in patients presenting with acute coronary syndromes
(ACS) who are treated with clopidogrel. However their contribution to high on-treatment
platelet reactivity (HPR) in clopidogrel treated Chinese patients is less known. As far as we
know, ticagrelor is not dependent on gene-based metabolic activation and demonstrated greater
clinical efficacy than clopidogrel in a recent secondary prevention trial. we will conduct an
interventional study to compare the antiplatelet efficiency between clopidogrel and
ticagrelor by the guidance of CYP450 2C19*2 (CYP2C19*2) , using Taqman genotyping method.